Omalizumab in the Treatment of Peanut Allergy

NCT00949078 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Food Allergy
Peanut Allergy

Interventions

DRUG: omalizumab

Sponsor

Johns Hopkins University

Collaborators

[object Object]